Yield10 Bioscience, Inc. operates as an agricultural bioscience company that focuses on commercializing products using the Camelina oilseeds in the United States. Its products include Camelina oil for production of high levels of the omega-3 fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA); and for use as a low-carbon intensity feedstock oil for biofuels, including biodiesel, renewable diesel (RD), and sustainable aviation fuel (SAF). The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was incorporated in 1992 and is headquartered in Woburn, Massachusetts. On December 6, 2024, Yield10 Bioscience, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on October 14, 2025.
0 transactions — 0 buys and 0 sales reported by Yield10 Bioscience, Inc. executives.
0 institutional funds report a position on YTENQ in their latest SEC quarterly filing.
Beyond raw data, we aggregate and score every smart money signal to give you a unique view.
8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.
Detection of clustered purchases or sales by several executives in the same stock.
Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.
NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.
Spot marked changes in search interest around the stocks being followed.
Create your watchlist and receive a brief of events affecting your tickers.
This public page only shows a preview. The full analysis of YTENQ on the Kairos Insider dashboard includes:
Free signup · Pro €19/month or €190/year